Tesaro shares skid low­er as As­traZeneca wows with PhI­II da­ta on PARP drug for ovar­i­an can­cer

As­traZeneca spelled out its im­pres­sive Phase III da­ta for Lyn­parza (ola­parib) pills, which will now line up against Tesaro’s ri­val PARP ni­ra­parib.

In a cen­tral, blind­ed re­view the drug achieved a me­di­an pro­gres­sion-free sur­vival rate of 30.2 months in germline BR­CA-mu­tat­ed, plat­inum-sen­si­tive, re­lapsed ovar­i­an can­cer pa­tients ver­sus 5.5 months for the place­bo arm. A sol­id suc­cess for As­traZeneca, which bad­ly needs to con­tin­ue to build up its on­col­o­gy group if CEO Pas­cal So­ri­ot ex­pects to achieve any­thing like the big turn­around he’s been promis­ing in­vestors for years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER